GBG Forschungs GmbH
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Private
- Established
- 2004-01-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.gbg.de
Capivasertib Plus Fulvestrant vs. Fulvestrant in Primary High-risk Lobular Breast Cancer
Phase 2
Recruiting
- Conditions
- CCCA Assessed by Ki67 Drop Below <2.7% From Baseline
- Interventions
- First Posted Date
- 2024-09-23
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- GBG Forschungs GmbH
- Target Recruit Count
- 120
- Registration Number
- NCT06607757
- Locations
- 🇩🇪
Hämato-Onkologie im Medicum - Onkologie und Hämatologie, Bremen, Germany
🇩🇪Carl-Thiem-Klinikum gGmbH - Frauenklinik, Cottbus, Germany
🇩🇪Kath. St. Paulus GmbH - Klinische Forschung, Dortmund, Germany
Sacituzumab Govitecan in Primary HER2-negative Breast Cancer
Phase 3
Active, not recruiting
- Conditions
- HER2-negative Breast CancerTriple Negative Breast Cancer
- Interventions
- First Posted Date
- 2020-10-20
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- GBG Forschungs GmbH
- Target Recruit Count
- 1332
- Registration Number
- NCT04595565
- Locations
- 🇪🇸
Hospital Universitario de Fuenlabrada, Fuenlabrada, Spain
🇪🇸Hospital Galdakao-Usansolo, Galdakao, Spain
🇪🇸Hospital Universitario Clinico San Cecilio, Granada, Spain
© Copyright 2025. All Rights Reserved by MedPath